Jim Mom­tazee's Pa­tient Square leads $150M+ ad­di­tion to Kriya Ther­a­peu­tic­s' 'main­stream' gene ther­a­py am­bi­tions

Shankar Ra­maswamy’s Kriya Ther­a­peu­tics has upped its Se­ries C with an ad­di­tion­al $150 mil­lion-plus to take the biotech in­to late 2026.

The AAV-fo­cused gene ther­a­py …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER